E
ESPR

Ergoteles’s Esperion Therapeutics ESPR Stock Holding History

Ergoteles’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-58,600
Closed -$81.5K – 307
2023
Q2 		$81.5K Buy
+58,600
New +$81.8K ﹤0.01% 929
2021
Q4 		– Sell
-48,200
Closed -$581K – 1334
2021
Q3 		$581K Buy
+48,200
New +$702K 0.02% 524

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ergoteles's ESPR Position: Q3 2023 in Review

Ergoteles sold out of Esperion Therapeutics (ESPR) in Q3 2023, closing a stake of 58,600 shares — an estimated $81.5K sold.

Ergoteles first reported a position in ESPR in Q3 2021 and held it in 2 quarters. The position peaked at $581K in Q3 2021. 122 funds tracked by Wall St. Rank hold ESPR as of Q3 2023.

  • Ergoteles reported no remaining Esperion Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 58,600 Esperion Therapeutics shares in Q3 2023, an estimated $81.5K.
  • Ergoteles first reported a position in Esperion Therapeutics in Q3 2021 and held it in 2 quarters.
  • Ergoteles's Esperion Therapeutics position peaked at $581K in Q3 2021.
  • 122 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.